{"entity":{"id":"paper-shaw-crizotinib-ros1-nejm-2014","kind":"paper","name":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","aka":[],"tldr":"Crizotinib shrank tumours in almost three quarters of patients with ROS1-rearranged lung cancer and controlled the disease for a median of 19 months, establishing ROS1 as a targetable driver and leading to the first approval.","summary":"Expansion cohort of a phase 1 study treating 50 patients with advanced ROS1-rearranged non-small-cell lung cancer with crizotinib 250 mg twice daily.\n\nObjective response was 72 percent with median duration of response 17.6 months and median progression-free survival 19.2 months; the safety profile matched that seen in ALK-positive disease.","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2014","url":"https://doi.org/10.1056/NEJMoa1406766"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/25264305/"}],"tags":[],"related":[],"cancers":["ros1-positive-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["crizotinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2014,"doi":"10.1056/NEJMoa1406766","pmid":"25264305","authors":"Shaw AT, Ou SH, Bang YJ, et al.","paperType":"observational","findings":["Objective response 72 percent.","Median progression-free survival 19.2 months."],"whatItMeans":"ROS1 testing became standard in lung adenocarcinoma; crizotinib was the first approved ROS1 inhibitor and remains an option, though entrectinib, repotrectinib and taletrectinib now offer brain penetration and resistance coverage.","caveats":["Single-arm study of 50 patients.","Poor brain penetration and the G2032R resistance mutation limit crizotinib."],"changedPractice":true,"participants":50},"route":"/key-papers/paper-shaw-crizotinib-ros1-nejm-2014/","neighbours":{"cancer":[{"id":"ros1-positive-nsclc","kind":"cancer","name":"ROS1-positive non-small-cell lung cancer","route":"/cancers/ros1-positive-nsclc/"}],"drug":[{"id":"crizotinib","kind":"drug","name":"Crizotinib","route":"/drugs/crizotinib/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}